19.86

0.35% -0.07

Relay Therapeutics Inc (RLAY)

Overview News Price History Option Chain Financials Why RLAY Down? Discussions Forecast

Relay Therapeutics Inc stock is traded at $19.86, with a volume of 1.53M. It is down -0.35% in the last 24 hours and up +4.09% over the past month. Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.

Previous Close:

$19.93

Open:

$19.62

24h Volume:

1.53M

Relative Volume:

0.41

Market Cap:

$4.35B

Revenue:

$10.68M

Net Income/Loss:

$-272.71M

P/E Ratio:

-12.69

EPS:

-1.565

Net Cash Flow:

$-213.38M

1W Performance:

+0.46%

1M Performance:

+4.09%

6M Performance:

+122.40%

1Y Performance:

+485.84%

1-Day Range:

$19.36

$20.00

1-Week Range:

$19.36

$20.71

52-Week Range:

$3.31

$20.79

Relay Therapeutics Inc Stock (RLAY) Company Profile

Name

Relay Therapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

617-370-8837

Address

60 HAMPSHIRE STREET, CAMBRIDGE

Employee

192

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

RLAY's Discussions on Twitter

Compare RLAY vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RLAY Relay Therapeutics Inc	19.86	4.40B	10.68M	-272.71M	-213.38M	-1.565
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-26-26	Upgrade	Oppenheimer	Perform → Outperform
Dec-12-25	Upgrade	Wells Fargo	Equal Weight → Overweight
Sep-04-25	Resumed	Guggenheim	Buy
Apr-17-25	Initiated	Wells Fargo	Equal Weight
Sep-10-24	Resumed	Goldman	Buy
Sep-10-24	Upgrade	Jefferies	Hold → Buy
Sep-10-24	Downgrade	Oppenheimer	Outperform → Perform
May-10-24	Upgrade	Barclays	Equal Weight → Overweight
Apr-20-23	Upgrade	Jefferies	Underperform → Hold
Apr-19-23	Upgrade	Raymond James	Outperform → Strong Buy
Apr-13-23	Initiated	Raymond James	Outperform
Feb-03-23	Initiated	Oppenheimer	Outperform
Sep-30-22	Initiated	Barclays	Equal Weight
Sep-02-22	Initiated	Stifel	Buy
Jun-06-22	Initiated	Jefferies	Underperform
Feb-01-22	Initiated	Berenberg	Buy
Jul-21-21	Initiated	BofA Securities	Buy
Dec-15-20	Reiterated	H.C. Wainwright	Buy
Dec-08-20	Initiated	JMP Securities	Mkt Outperform
Nov-05-20	Initiated	H.C. Wainwright	Buy
Aug-10-20	Initiated	Cowen	Outperform
Aug-10-20	Initiated	Goldman	Buy
Aug-10-20	Initiated	Guggenheim	Buy
Aug-10-20	Initiated	JP Morgan	Neutral

View All

Relay Therapeutics Inc Stock (RLAY) Latest News

01:59 AM

Relay Therapeutics (NASDAQ:RLAY) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat

01:59 AM

Aug 14, 2026

PERCEPTIVE ADVISORS LLC Expands Relay Therapeutics Inc (RLAY) St - GuruFocus

Aug 14, 2026

Relay Therapeutics (RLAY): Commodore Capital group discloses 12M-share, 5.5% position - Stock Titan

Aug 14, 2026

RLAY Maintained by JP Morgan -- Price Target Raised to $31.00 - GuruFocus

Aug 14, 2026

Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat

Aug 14, 2026

Aug 13, 2026

Relay Therapeutics Stock Is Up Nearly 500% Over the Past Year - inkl.com

Aug 13, 2026